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Moving Beyond the Picos: APPRoPRiAte coMPARAtive oBseRvAtionAl 
dAtA selection cAn FAcilitAte MetA-AnAlysis oF RelAtive tReAtMent 
eFFects
Sallum R1, Zhang Y2, Xu Y1
1Evidera, Lexington, MA, USA, 2Evidera, London, UK
Evidence synthesis based on the quantitative analysis (indirect treatment com-
parisons ITC) of data from randomized controlled trials (RCTs) is the gold standard 
in healthcare decision making. However, when ITC of RCTs may not be practical or 
possible, comparative observational data may provide a valuable alternative despite 
potential challenges with internal validity. The present project aims to develop a 
conceptual framework from which valid quantitative assessment of real-world evi-
dence (RWE) can provide necessary insights into treatment effects outside the RCT 
settings. Considerations of quantitative evidence synthesis in RWE were identified 
using published best-practice guidelines for quantitative analysis of RCT data and 
applied to two test cases, atrial fibrillation (AF) treated with novel oral anticoagulant 
(NOAC) and type II diabetes treated with antihyperglycemic agents. Data sources of 
RWE, sample selection, outcome definitions, and statistical method variation were 
assessed. Significant variations across all key factors were observed in studies for 
both indications. In the case of NOAC treated AF, homogeneity of the data source 
and geographic location did not guarantee appropriate quantitative comparison. 
Several factors unique to assessing observational database study comparability for 
meta-analyses were identified including a need for a greater focus on selection bias 
inherent to the type and location of the database and increased sensitivity of esti-
mates to the index dates particularly in relation to local and international product 
launches, as well various outcome definition and reporting complexities. Valid ITC 
could be performed using RWE from comparative observational studies. Careful 
selection of studies is required to mitigate factors that would otherwise compro-
mise results through uncontrolled bias. Researchers need to go beyond the obvious 
individual study reporting biases and fully assess the complexities of comparative 
data sources to be able to appropriately select studies for ITC.
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PuBlic consultAtions: A tool FoR the inclusion oF society in the 
BRAziliAn htA PRocess
Silva AS, DA Silveira LC
Brazilian Ministry of Health, Brasília, Brazil
The participation of society in HTA is crucial and needs to be implemented. In the 
last years, it has been analyzing, discussing, and questioning how to actually intro-
duce the public’s participation into HTA processes within the Brazilian Public Health 
System (SUS) perspective. In 2011, Law 12,401 was enacted, making the participation 
of civil society official within the process of incorporating technologies in the health 
system through: the participation of a representative of the National Health Council 
(CNS) on the National Committee for Health Technology Incorporation (CONITEC); 
the execution of a Public Consultation (PC) for each theme evaluated by CONITEC; 
and through a Public Hearing prior to final decision-making, in case the relevance of 
the matter should justify such a hearing. The aim of this abstract is to describe the 
activities which are being developed after a study published in 2013 which identified 
proposals for improving the mechanisms of society’s involvement in the processes 
of the assessment and incorporation of technologies into the SUS. Many of these 
proposals, among others, are being implemented by the Executive Secretariat of 
the CONITEC. Some of those proposals were to improve its disclosure and to attain 
a better use of social media. We started to disseminate information regarding PC 
through social network, website and mailing lists to the interested audiences, in 
addition to producing reports in an appropriate language for patients, which was 
another proposal made previously by the cited study. Furthermore, a new PC form 
was especially created in order to report the society’s perspective (patients, caregiv-
ers and health professionals’ experiences) and a Guide to HTA for Patients is also 
being produced. Public Consultations as a tool for the inclusion of society in HTA is 
legitimate and innovative; improve this will increase Patient and Public Involvement 
in the Brazilian HTA process.
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Assessing heteRogeneity AcRoss gRouPs oF clinicAl tRiAls BAsed on 
AggRegAte dAtA
Schmidt H1, Koegler H2, Geier S2, Glaab T2, Metzdorf N2
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Meta-analyses in the classical sense, comparing two treatments across clinical tri-
als, are used for information synthesis during all phases of clinical research and 
development and especially in the context of reimbursement and assessment of 
relative effectiveness. In this meta-analytic framework we examined consistency 
of the relative treatment effect between groups of trials by application of a test for 
subgroup heterogeneity using aggregate trial data. A wide variety of software for 
performing meta-analyses and testing subgroup heterogeneity can be used, rang-
ing from ready-to-use systems like the Cochrane Collaboration’s RevMan software 
to packages requiring statistical expert knowledge. We applied this software and 
illustrate examination of heterogeneity in groups of trials by several examples. 
The first example investigates heterogeneity between groups of trials comparing 
different long-acting β 2-agonists (LABAs) versus Placebo with regard to exacerba-
tions in Chronic Obstructive Pulmonary Disease (COPD). Absence of heterogeneity 
was demonstrated and, hence, it turned out that the beneficial effect of Tiotropium 
in preventing COPD exacerbations, as e.g. directly demonstrated versus the LABA 
Salmeterol in the POET-COPD©trial, can be extended versus various LABAs. The 
second example examines heterogeneity in quality of life (QoL) as measured by the 
Saint George’s Respiratory Questionnaire (SGRQ) across Placebo-controlled COPD 
trial groups where Tiotropium was administered either open-label or blinded. It 
was shown that the magnitude of response with this QoL measure is inconsistent 
between open-label and blinded administration of Tiotropium with a higher benefit 
1Velammal Medical College Hospital and Research Institute, Madurai, India, 2MarksMan 
Healthcare Solutions LLP (HEOR and RWE Consulting), Navi Mumbai, India
BAckground: Treatments associated with excellent outcomes in a research set-
ting in randomised controlled trials (RCTs) may not be beneficial in the real-world 
settings which has a different spectrum of patients in different clinical situations. 
Therefore, healthcare providers are looking for evidence in the real-world setting in 
addition to RCTs. In this background, health insurance claims data are a source of 
invaluable real-world data. Claims data are increasingly being used for pharmaco-
economic and outcomes researchin regions like North America, Europe, Australia, 
and New Zealand. The major advantages of claims data over RCT data include: (a) 
health outcomes can be evaluated in real-world settings; (b) analysis results can 
be generalised to a broader population; (c) relatively inexpensivethan RCTs; (d) 
provide wide range of information about various conditions and procedures from 
a large number of patients, belonging to varied demographics; (e) data availability 
over extended periods of time allow retrospective cohort studies; (f) unaffected by 
recall bias; (g) large sample size will make the statistical methods more consistent. 
However, there are some limitations as well, such as incomplete diagnostic and 
provider identification data, and the fact that the population characteristics are 
largely influenced by the insurance plan, plan benefit design, and the variables 
of the database. Claims data in India are insufficiently used for health outcomes 
research. An important reason for this is that the penetration of health insurance is 
not up to the mark in India. It is expected that health insurance will become more 
popular in India, since (a) Indian health care expenditure is predominantly out-of-
pocket, and (b) the healthcare costs are escalating day-by-day. RECOMMENDATIONS: 
With the increased penetration of health insurance in India, appropriate analysis 
of the resulting claims data can provide invaluable insights into demographics, 
disease trends, efficacy and effectiveness, and real-world information, from the 
Indian perspective.
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PossiBle APPlicAtions oF ReAl WoRld evidence in sAFety oPeRAtions
Kaneria J, Bhutani MK, Goyal R, Rai MK
Tata Consultancy Services, Mumbai, India
Regulatory agencies are providing market authorization of pharmaceutical prod-
uct solely on the basis of efficacy, compliance and side effects derived from ran-
domised clinical trials (RCTs) which frequently fail to reflect real time use. It is 
important for the pharmaceutical companies and regulatory agencies to ensure 
that drug is performing well in the real world as it does in the closely monitored 
world of clinical trials. The payers like Medicare and Medicaid in the United States 
are also emphasizing on the drug benefits in real clinical practice. Also, the recent 
amendments in European Pharmacovigilance legislation emphasize continuous 
risk benefit assessment/risk management of pharmaceutical product following its 
launch in European market. Thereby, sources of good quality RWE will be essen-
tial for companies to meet regulatory authority expectations. The key activities 
within the area of Risk Management include compilation of Risk Management 
Plans (RMPs) and aggregate reports such as the Periodic Safety Update Report 
(PSUR), Periodic Benefit Risk Evaluation Report (PBRER), and the Development 
Safety Update Report (DSUR). These pharmacovigilance competencies can prove 
to be very useful in identifying drug’s risk-benefit profile which includes potential 
safety concerns, risk factors, effectiveness measures, safety signals, and target 
population. By leveraging database and observational studies, signal detection 
algorithms, surveys and extensive pharmacovigilance competencies, following 
research objectives can be achieved with Real World Safety evidence: Define drug 
exposure; Assess the epidemiology of indication/target population; Identify poten-
tial safety concerns and characterize known risk factors; Determine prescrib-
ing conditions/patient characteristics for drugs; Determine the effectiveness of 
measures to minimize risk; Identify and evaluate safety signals in a systemized 
way; The above mentioned concepts can serve as a precursor for planning of RWE; 
prospective and retrospective studies which can lead to potential cost saving and 
efficient analysis of the safety apprehensions.
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huMAn heAlth dAMAge Modelling in liFe cycle AssessMent: A 
vAluABle Addition to the evAluAtion oF MedicAl inteRventions?
Debaveye S1, De Soete W1, De Meester S1, Vandijck D1, Heirman B2, Kavanagh S2, Dewulf J1
1Ghent University, Gent, Belgium, 2Johnson & Johnson, Beerse, Belgium
Current practice in Life Cycle Assessment (LCA) has, until now, focused predomi-
nantly on charting the environmental footprint of products and systems in vari-
ous industries. LCA studies typically report the environmental damage on three 
Areas of Protection: Natural Resources, Ecosystem Quality and Human Health. 
The damage results from the cause-effect chain of the use of natural resources 
and the release of emissions during the life cycle of any product. The third Area 
of Protection Human health is based on e.g. particulate matter emissions causing 
respiratory diseases and health effects related to global warming such as a higher 
incidence of food and waterborne diseases or natural disasters. These effects are 
gathered under a common unit: the Disability Adjusted Life Year (DALY), which 
accounts for both the morbidity and mortality of diseases. In the pharmaceutical 
sector, several LCA studies have evaluated different parts of the supply chain. Drug 
production, patient transport and hospital heating all contribute to the global 
environmental damage, including Human Health, of a full medical treatment. 
However, medical interventions are predominantly evaluated on their treatment 
benefits and risks in terms of how a patient feels, functions and survives. In 
addition, their costs and benefits are also weighted against each other in order 
to define the cost-effectiveness of a medical treatment. We propose the addition 
of the environmental health burden to the current evaluation methodologies of 
a medical treatment. This would allow for a more holistic appraisal, taking into 
account the effects of health care indirect resource use and emissions. The exist-
ing state of the art methodology for the quantification of environmental Human 
Health damage is discussed.
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PRevention And tReAtMent oF Missing dAtA in ReAl WoRld ReseARch
Gemmen E
Quintiles, Inc., Rockville, MD, USA
PurPose: The objective of this presentation is to bring awareness to the challenges of 
missing data from study design and analysis perspectives, and to discuss study design 
elements and analysis methods that support meaningful and valid inferences in both 
prospective and retrospective observational research used to generate real-world 
evidence for payers and health technology assessment authorities. descriPtion: 
Observational studies are increasingly used to study the post approval drug exposed 
population for drug and medical effectiveness and safety assessments. Understanding 
the potential sources of missing data from a study whose design imposes structure on 
data captured from real world clinical practice allows the selection of study design ele-
ments that may help reduce the magnitude of missing data. Given the occurrence of 
missing data, analysis methods that support valid and meaningful conclusions from 
observational research are necessary. This presentation starts with an overview of the 
potential sources of missing data in observational research, including PRO assess-
ments and retrospective clinical data; then focuses on proactive planning of data 
collection and analysis. The types of missing data (missing due to study withdrawal; 
directly reported as missing; non-reported; uninterpretable value; out-of-range value) 
and statistical approaches for handling missing data including examining missing 
data patterns and testing missingness mechanisms, effective and advanced analytic 
methods (imputation, likelihood based and weighted approaches), when these meth-
ods should be applied, and the impact of missing data to the interpretation of study 
findings will be discussed. The concepts and methods will be explained with the use 
of real-world observational study data, including patient registries, electronic medical 
records, patient charts, and claims data.
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sugAMMAdex: the Right oPtion FoR the eFFiciency oF the oPeRAting 
RooM? A Methodology FoR cost / BeneFit AnAlysis in coMPARison to 
the Routine choice FoR ReveRsAl
Ronco GL
Emmonos S.A., Fenegro’, Italy
BAckground: In face to the financial environment in which health facilities cur-
rently are evolving, it is now clear and shared that only through a good organization 
of the surgical event it is possible to achieve significant improvements in quality 
of care. In this way the economic impact becomes inversely proportional because 
the establish oneself of the virtuous circle that leads (or at least should lead) to 
a adequate request of resources that are used in a so much appropriate way to 
obtain the most practical benefit that ultimately produces case-mixes with high 
profitability, a good level of quality perceived as high and expenses pragmatically 
supported by the revenues. endpoints The primary endpoint of this study aims to 
assess, starting from the costs that the information analyzed allow to accurately 
calculate, the increased efficiency achieved by the availability to the anesthesiologist 
of sugammadex rather than its unavailability. Moreover, the secondary endpoint 
aims to formulate organizational scenarios to permit the unlimited use of sugam-
madex rather than have availability of it in a controlled amount for use based on a 
protocol. Furthermore, it tries to identify the surgical specialties in which each of 
the two scenarios can be applied with the highest profit. Methodology The Cost / 
Benefit Analysis (CBA) requires that the clinical indicators obtained be monetized 
by referring to cost and revenue. It is essential retrieve the information from the 
anesthesiology medical records (the prerequisite of validity for inclusion of the 
anesthesiology medical record is the presence of observation of the state of neu-
romuscular blockade by use of objective monitoring tools). Furthermore, it needs 
to retrieve the costs of the activity of the operating theatre from the management 
control system of the hospital. The revenues come from the clinical medical records.
diseAse- sPeciFic studies
individuAl’s heAlth – clinical outcomes studies
Pih1
A cost-eFFectiveness AnAlysis oF hosPitAl PhARMAcist RevieW in 
oldeR PAtients
Gallagher J1, O’Sullivan  D1, Mc Carthy S1, Gillespie P2, Woods N1, O’Mahony D3, Byrne S1
1University College Cork, Cork, Ireland, 2National University of Ireland Galway, Galway, Ireland, 
3Cork University Hospital, Cork, Ireland
oBjectives: A recent cluster randomised controlled trial (RCT) conducted in an 
Irish hospital evaluating a structured pharmacist review of medication (SPRM) sup-
ported by computerised decision support software (CDSS) demonstrated positive 
outcomes in terms of reduction of adverse drug reactions (ADR). The aim of this 
study was to examine the cost-effectiveness of pharmacists applying a SPRM in 
conjunction with CDSS to older hospitalised patients compared to usual pharma-
ceutical care. Methods: Cost-effectiveness analysis alongside a cluster RCT. The 
trial was conducted in a tertiary hospital in the south of Ireland. The intervention 
arm patients (n= 361) received a multi-factorial intervention consisting of medicines 
reconciliation, deployment of CDSS and generation of pharmaceutical care plan for 
patient. Control arm patients (n= 376) received usual care from the hospital phar-
macy team. Incremental cost-effectiveness was examined in terms of costs to the 
healthcare system and an outcome measure of ADRs during an inpatient hospital 
stay. Uncertainty in the analysis was explored using a cost-effectiveness accept-
ability curve (CEAC). results: On average, the intervention arm was the dominant 
strategy in terms of cost-effectiveness. Compared to standard care (control), the 
intervention was associated with a decrease of € 815 (95% Confidence intervals (CI) 
-3451, 1820) (p = 0.544) in mean healthcare cost and a decrease in the mean number 
of ADR events per patient of -0.064 (95% CI -0.135, 0.008) (p = 0.081). The probability of 
the intervention being cost-effective at respective threshold values of € 0, € 250, € 500, 
for Tiotropium seen in blinded trials. Our examples demonstrate the useful applica-
tion of classical meta-analytic methods to assess heterogeneity across groups of 
trials based on aggregate data of relative treatment effect and its variability.
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vAlue-BAsed PRicing scheMe FoR neW technology in consideRAtion 
oF cost-eFFectiveness doMinAnce to the contRol
Kamae I1, Sugimoto T1, Yamabe K2
1The University of Tokyo, Graduate School of Public Policy, Tokyo, Japan, 2Takeda Pharmaceutical 
Company Ltd., and The University of Tokyo, Tokyo, Japan
oBjectives: This study aims to develop a theoretical scheme to achieve value-
based pricing in consideration of the efficiency with respect to the cost-effective-
ness dominance of a new technology, compared to the best control or the next best 
one. Methods: Suppose that a pair of cost and benefit of a new technology, the 
best control and next best one is respectively represented as three points with X(Ex, 
Cx), S(Es, Cs) and S’(Es’, Cs’) on the cost-effectiveness plane, assuming the inequali-
ties Es’ < Es < Ex and Cs’ < Cs < Cx. Let Cx be a variable, while the other parameters 
all constant. Considering geometric relations between the three points, we iden-
tify the areas where point X should be located according to the categories: simple 
dominance, extended dominance and non-dominance, in which we formulate the 
association between the expected cost Cx and the incremental cost-effectiveness 
ratio (ICER) of point X: (Cx - Cs)/(Ex - Es) compared to point S and (Cx - Cs’)/(Ex - Es’) 
to point S’. results: Three ranges for Cx were identified for each of the dominance 
categories, respectively, 1) lower than Cs’, 2 ) between Cs’ and Cm, and 3) greater 
than Cm, where Cm was estimated with the expression of ((Ex - Es’)Cs - (Ex - Es)Cs’)/
(Es - Es’). The expected cost Cx was formulated as a linear function of the ICER: Cx = 
Cs’ + (Ex - Es’)*ICERs’-x in case of dominance, whether simple or extended, and Cx = 
Cs + (Ex - Es)*ICERs-x for non-dominance. Based on the formulae, the maximal cost 
accepted in each category was determined in theory and with examples, taking an 
ICER threshold into account. conclusions: Our approach will provide decision 
makers with a scientific scheme for value-based pricing, and clarify the value position 
in consideration of economic efficiency.
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htA studies FoR MedicAl devices incoRPoRAting theiR MoRAl Ageing
Kamensky V, Rogalewicz V, Fortova B, Simackova J, Kneppo P
Czech Technical University in Prague, Kladno, Czech Republic
oBjectives: Due to specificities of medical devices (short lifetime, learning curve, 
limited approval process, steady technological development, etc.), it is desirable to 
take account of moral aging in HTA studies focused on devices. However, methods that 
might be used to evaluate innovations that are brought by a new generation of instru-
ments (and consider them in assessments of the older ones) are not well defined 
yet, although they are considered topical by many recent journal and conference 
papers. Methods: The paper consists of two parts. First, the history of innovations 
and their incorporation in HTA studies was studied for three typical devices (stents, 
MRI, left ventricular assist device – LVAD) with the focus on the delays in the particu-
lar analyses. Second, based on a literary review, a recommendation was formulated 
for assessment of devices in the case when innovations appear rapidly after each 
other. results: It is shown that older generations of devices are often being assessed 
when substantial innovations are already available, without taking them into con-
sideration. Classic CEA is probably difficult to apply. Two possible approaches were 
selected: MCDA applied on the effect side of the CEA (a modification of the method 
suggested by Rosina et al., Lékař a technika 44(3), 2014, 23-36), and the headroom 
method (Cosh et al., J Commer Biotechnol 13(4), 2007, 263-71). Their application is 
illustrated in the case of LVAD. CONCLUSION: The current methodologies for medi-
cal device assessment do not consider their moral ageing and/or innovations. The 
headroom method and/or MCDA may be a partial solution, as this paper suggests. 
Further more extensive studies are necessary in this direction.
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clinicAl Multi-cRiteRiA decision AssessMent (cMdA): A PRoPosAl 
FoR APPlying McdA to coMPARe tReAtMents in A siMultAneous, 
tRAnsPARent And oveRAll WAy
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There are plenty of different clinical and economic parameters to consider in order 
to choose the best treatments. RCT and consequent Mixed Treatment Comparison 
(MTC) are based on the assessment of one single criterion, we need to move to a 
transparent and systematic framework enabling decision makers to assess all rel-
evant parameters simultaneously in order to evaluate the best intervention. In order 
to apply the Multiple Criteria Decision Analysis (MCDA) methodology to both clinical 
setting and decision making process we suggest the application of a model of MCDA 
as Clinical Multi-criteria Decision Assessment (CMDA). In this model of CMDA, we 
apply the methodology of MCDA in the context of a single disease, ie to compare 
biologicals in rheumatoid arthritis. Like for the general framework of MCDA, in 
CMDA there is not one predominant criterion; the innovative approach is to consider 
a “clinical consensus” for the selection of all relevant criteria (domains) and related 
parameters for evaluation, and the following attribution of specific weights. This 
means that clinical outcome measured on a specific endpoint (parameters) will 
be weighted according to the importance that a clinical consensus will give to the 
specific domain. This helps guaranty a transparent and objective evaluation. Results 
from both meta-analysis and observational studies are used by a clinical consensus 
after attributing weights to specific domains and related parameters. Decision will 
result from a related comparison of all parameters (i.e. efficacy, safety). The match 
will yield a score (in absolute value) that link each parameter with a specific inter-
vention, and then a final score for each treatment. The higher is the final score; the 
most appropriate is the intervention to treat disease considering all criteria (domain 
and parameters). The results will allow physicians evaluate best clinical treatment 
considering at the same time all relevant criteria.
